| Cerebrovascular systemic diseases are common ailments and frequently occurring illnesses in our country, which attack rate and death rate are higher than any other systemic diseases. Many studies shows most of cardiovascular diseases were closely correlated with thrombogenesis and thromboembolism. So, the exploitation of antithrombotics has become a focus in new drugs'study field.Since it has been reported that pyridazinone derivates had the activity of anti-inflammatory and depressurization in 1976, people found such kind of compounds possessed many biological activities and many of that had good antiplatelet aggregative and cardiotonic activities, such as CI-914,C1-930,MCI-154, CCI-17810, levosimendan, pimobendan and so on, among which levosimendan and pimobendan were on sale. On the base of many protophase researches, the topic was designed according to mechanism of action and structure-activity relationship of dihydropyridazinone compounds. MCI-154 was regarded as leading compound and the elementary structure of dihydropyridazinone was remained. While the chloracetyl group was used as connection group,then carbon chain including various kinds of side chain and heterocyclic ring can be extended. Many reactions such as Friedel-Crafts reaction, hydrolysis, cyclization and acylation reactions were used to synthesize thirty title compounds, in which twenty nine of them were firstly reported. All the title compounds were confirmed by element analysis, 1H-NMR, and IR.Born method was applied for preliminary pharmacological test in vitro. Result of preliminary pharmacological tests showed that all title compounds exhibited potent inhibiting activity against platelet aggregation induced by ADP to a certain extent in vitro. The IC50 values of compounds (B3),(B5),(C8),(C11) are respectively 2.70,2.43,2.81,2.28μmol/L. They are more potent than the leading compound MCI-154 (MCI-154's IC50 is 13.95μmol/L) and the control compound CCI-17810 (CCI-17810's IC50 is 18.60μmol/L).
|
PDF Full Text Request